• HBM Healthcare Investments closed the previously announced sale of a majority stake in Swixx Biopharma to funds advised by SK Capital Partners, Bain Capital Life Sciences.
• HBM retained an about 8% stake in Swixx Biopharma, remaining a significant minority shareholder alongside founders, management, SK, Bain, Mérieux.
• The Swixx investment, held since 2017, ranks as HBM’s most successful investment to date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.